Moderna’s (MRNA) Buy Rating Reiterated at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their buy rating on shares of Moderna (NASDAQ:MRNA) in a research note published on Sunday morning, AnalystRatings.com reports. JPMorgan Chase & Co. currently has a $24.00 price target on the stock.
Several other analysts also recently commented on the stock. Piper Jaffray Companies raised their price objective on shares of Moderna from $24.00 to $30.00 and gave the stock an overweight rating in a research report on Wednesday, May 8th. Oppenheimer raised their price objective on shares of Moderna from $27.00 to $31.00 and gave the stock an outperform rating in a research report on Wednesday, May 29th. Chardan Capital reaffirmed a buy rating and set a $40.00 price objective on shares of Moderna in a research report on Sunday, June 2nd. Finally, Zacks Investment Research raised shares of Moderna from a hold rating to a buy rating and set a $15.00 price objective for the company in a research report on Saturday, August 10th. Ten analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and an average price target of $26.30.
Shares of MRNA stock opened at $12.74 on Friday. The firm has a market cap of $4.39 billion and a P/E ratio of -2.57. Moderna has a 52 week low of $11.54 and a 52 week high of $29.79. The stock’s 50 day moving average is $13.88.
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Featured Article: What is a trade deficit?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.